← All ABD Flashcard Decks

Cutaneous Oncology Flashcards

7 cards from real ABD practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Cutaneous Oncology flashcards as text
  1. Muir-Torre syndrome links sebaceous neoplasms with an increased risk of which internal malignancy?

    Answer: Colorectal and other Lynch-spectrum cancers

    Muir-Torre is a variant of Lynch syndrome with mismatch-repair defects predisposing to colorectal and genitourinary cancers.

  2. Which stain best highlights the eccrine ductal differentiation of microcystic adnexal carcinoma versus a benign syringoma?

    Answer: Depth of infiltration and perineural invasion on excision

    MAC is distinguished from syringoma largely by its deep infiltrative growth and perineural invasion rather than by a single stain.

  3. The AJCC 8th edition changed melanoma T-staging by adding which factor for T1 tumors?

    Answer: Ulceration and a 0.8 mm cutoff defining T1a vs T1b

    In AJCC 8, T1b is defined by thickness ≥0.8 mm or ulceration, and mitotic rate was removed as a T-category criterion.

  4. Angiosarcoma of the scalp in elderly patients typically presents as:

    Answer: A bruise-like violaceous plaque that enlarges

    Cutaneous angiosarcoma often mimics a persistent, enlarging bruise on the scalp or face of older adults.

  5. Which vascular tumor is associated with HHV-8 and immunosuppression?

    Answer: Kaposi sarcoma

    Kaposi sarcoma is driven by human herpesvirus 8 and is common in immunosuppressed or HIV-positive patients.

  6. For low-risk actinic keratoses, field therapy commonly uses which agent?

    Answer: Topical 5-fluorouracil

    Topical 5-FU is a standard field-directed treatment for multiple actinic keratoses.

  7. Nicotinamide (vitamin B3) supplementation has been shown to do what in high-risk patients?

    Answer: Reduce the rate of new keratinocyte carcinomas and actinic keratoses

    Oral nicotinamide reduces incidence of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.